Tiziana Life Sciences PLC's (LON:TILS) (NASDAQ:TLSA) CEO Kunwar Shailubhai speaks to Proactive's Andrew Scott following the news they're collaborating with Parexel Biotech to conduct a global Phase 1b/2 trial with enteric-coated capsules of formulated Foralumab as a therapy for patients with moderate to severe Crohn’s Disease. The study will evaluate the safety, tolerability, and clinical activity of escalating doses of orally administered capsules of Foralumab.